[15] reported that mesenchymal stromal cells that were genetically engineered to overexpress IGF-1 enhanced the effects of cell-based gene therapy for renal failure-induced anemia treated with IGF-1 and that IGF-1-mediated proliferation might play a role in this process. The gene discussed is IGF1; the disease is acute kidney injury.